Axial Biotherapeutics is the latest microbiome firm to emerge. Private and venture capital investors, including Longwood Fund and Domain Associates, have put an initial $19 million into the California start-up.
Axial is based on the work of California Institute of Technology professor Sarkis Mazmanian. In mouse models, his lab has shown a connection between neurological disorders and interventions in the gut microbiome. Axial intends to expand on these discoveries to find pathways and mechanisms amenable to biotherapeutic intervention. Initial disease targets include autism and Parkinson’s disease.
Technology that Axial has licensed from Caltech includes Mazmanian’s work involving Bacteroides fragiles. Raising the level of these gut bacteria can reduce autism-like behavior in engineered mice.
Axial Biotherapeutics total Funding
Axial Biotherapeutics latest funding size
Time since last funding
|a year ago|
Axial Biotherapeutics investors
|Seventure Partners, Domain Associates, Longwood Founders Fund, Taiho Ventures, Health for Life Capital fund, Kairos Venture Investments, Longwood Fund, Heritage Medical Center|
When was Axial Biotherapeutics founded?
Axial Biotherapeutics was founded in 2013.
Who are Axial Biotherapeutics key executives?
Axial Biotherapeutics's key executives are Eric de la Fortelle, Scott C. Brun and Sakae Asanuma.
Who are Axial Biotherapeutics competitors?
Competitors of Axial Biotherapeutics include Principia BioPharma, Vectura Group and Chiasma.
Where is Axial Biotherapeutics headquarters?
Axial Biotherapeutics headquarters is located at 9 4th Ave, Waltham.
Where are Axial Biotherapeutics offices?
Axial Biotherapeutics has an office in Waltham.
How many offices does Axial Biotherapeutics have?
Axial Biotherapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies